مباشر
FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentFierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonistsBioWorldIteos Belgium discloses new PTPN1/2 inhibitorsBioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIVBioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent
Bio-Rad ٣٠ أبريل ٢٠٢٦

Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan

Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.